



TARGET  OL

2016-2017

INHIBITORS OF SIGNALING PATHWAYS

Inhibitors, Libraries, Natural Compounds

About us


Target Molecule Corp. (TargetMol) is a global high-tech enterprise, specializing in chemical and biological research products and services. With the help of fast and efficient global supply chain, professional and rigorous procurement process and timely dynamic news of products, you will save more time with less cost and lead in drug discovery and screening.

Our Product Portfolio

Inhibitor

Targetmol supplies **over 3000** compounds used in the study of cell signaling pathways and drug discovery. Track the latest scientific research and promptly offer the newest and most popular inhibitors.

- 50~100 new inhibitors per month.
- NMR and HPLC validated to ensure high purity.
- Above 95% compounds are in stock.




Compound Libraries

Targetmol provides **more than 32** types of compound libraries. They are available for **cell induction, signaling pathway and HTS**. Compound libraries are useful professional tools for drug discovery and new indication research. Customers can customize individual libraries by selecting specific molecules, quantities, concentrations, and format.

Contents

Proteases/Proteasome.....	4
Chromatin/Epigenetics	5
JAK/STAT Signaling	8
PI3K/Akt/mTOR Signaling.....	9
Tyrosine Kinase/Adaptors.....	12
MAPK Signaling.....	16
Cell Cycle/Checkpoint.....	18
Stem Cell.....	20
Apoptosis	21
Ubiquitination	23
Angiogenesis	24
Immunology/Inflammation.....	25
Membrane Transporter/Ion Channel	26
DNA Damage/DNA Repair	27
Neuroscience	28
Microbiology & Virology	29
GPCR/G Protein	30
Endocrinology/ Hormones	32
Metabolism.....	33
Enzyme.....	34
Others	34

Proteases/Proteasome




Proteasome

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2399	Bortezomib (PS-341)	179324-69-7	Selective	20S proteasome	(Ki) 0.6 nM	FDA Approved	Mantle-cell lymphoma; Multiple myeloma
T2154	MG-132	133407-82-6	Selective	20S proteasome	100 nM		
T1795	Carfilzomib (PR-171)	868540-17-4	Selective	20S proteasome	<5 nM	FDA Approved	Multiple myeloma
T2016	MLN9708	1201902-80-8	Selective	LMP7	10 nM		

For more products information, please check our website of "www.targetmol.com".

Chromatin/Epigenetics



Epigenetic Reader Domain

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2110	(+)-JQ-1	1268524-70-4	Selective	BRD4(1) BRD4(2)	77 nM 33 nM		
T2480 NEW	RVX-208	1044870-39-4	Selective	BD2	0.51 μM	Phase 2	Diabetes
T1906 NEW	GSK-525762A (I-BET-762)	1260907-17-2	Pan	BET proteins	~35 nM		
T2442 NEW	CPI-203	202591-23-9	Selective	BRD4	37		
T2379 NEW	UNC1215	1415800-43-9	Selective	L3MBTL3	40		

For more products information, please check our website of "www.targetmol.com".

Aurora Kinase

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T3068	AT9283	896466-04-9	Selective	Aurora A	3 nM	Phase 1	Non-Hodgkins Lymphoma; Unspecified Adult Solid Tumor
				Aurora B	3 nM		
T2241	MLN8237 (Alisertib)	1028486-01-2	Selective	Aurora A	1.2 nM	Phase 3	Advanced Solid Tumors; Relapsed Lymphoma
				Aurora B	396.5 nM		
T2509	VX-680 (Tozasertib, MK-0457)	639089-54-6	Pan	Aurora A	Ki (0.6 nM)	Phase 2	Advanced Cancer
				Aurora B	Ki (18 nM)		
				Aurora C	Ki (4.6 nM)		
T2602	Barasertib (AZD1152-HQPA)	722544-51-6	Selective	Aurora B	0.37 nM	Phase 1	Acute Myeloid Leukaemia
				Aurora A	1368 nM		
T2617	SNS-314 Mesylate	1146618-41-8	Pan	Aurora A	9 nM	Phase 1	
				Aurora B	31 nM		
				Aurora C	3 nM		

HDAC

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6233	Entinostat (MS-275)	209783-80-2	Pan	HDAC1	0.51 μ M	Phase 2	Non-Small Cell Lung Cancer
				HDAC3	1.7 μ M		
T2383	Panobinostat (LBH589)	404950-80-7	Pan	HDAC	5 nM	Phase 3	
T6270	Trichostatin A	58880-19-6	Pan	HDAC	~1.8 nM		
T1857 NEW	TMP269	1314890-29-3	Pan	HDAC4	157 nM		
				HDAC5	97 nM		
				HDAC7	43 nM		
				HDAC9	23 nM		
T1819 NEW	Nexturastat A	1403783-31-2	Selective	HDAC6	5 nM		
T1762	RGFP 966	1357389-11-7	Selective	HDAC3	0.08 μ M		

PARP

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6224	Iniparibnb(BSI-201)	160003-66-7	Selective	PARP1	N/A	Phase 2	Breast Cancer
T3015	Olaparib (AZD2281, Ku-0059436)	763113-22-0	Pan	PARP1	5 nM	Phase 2	Cancer
				PARP2	1nM		
T2591	Veliparib(ABT-888)	912444-00-9	Pan	PARP1	Ki(5.2 nM)	Phase 3	
				PARP2	Ki(2.9 nM)		

For more products information , please check our website of "www.targetmol.com".

Histone Methyltransferase


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T3099	EPZ5676	1380288-87-8	Selective	DOT1L	Ki(80 pM)	Phase 1	
T1905	EPZ005687	1396772-26-1	Selective	EZH2	Ki(24 nM)		
T1959	BIX 01294	1392399-03-9	Selective	G9a	2.7 μ M		
T3082	SGC0946	1561178-17-3	Selective	DOT1L	0.3 nM		
T3057 NEW	UNC1999	1431612-23-5	Selective	EZH2	2 nM		
				EZH1	45 nM		
T3081 NEW	EPZ004777	1338466-77-5	Selective	DOT1L	0.3 nM		

Sirtuin

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6111	EX 527 (Selisistat)	49843-98-3	Selective	SIRT1	38 nM		
T6671	Sirtinol	410536-97-9	Pan	SIRT1	131 μ M		
				SIRT2	38 μ M		
T2412	SRT1720	1001645-58-4	Selective	SIRT1 (activator)	EC ₅₀ (0.16 μ M)		
T2174	Quercetin	117-39-5	Selective	SIRT1 (activator)		Phase 3	Thromboembolism

For more products information, please check our website of "www.targetmol.com".

JAK/STAT Signaling



JAK

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T3043	Ruxolitinib (INCB-18424) phosphate	1092939-17-7	Pan	JAK1	3.3 nM	FDA Approved	Oxidative Stress
T3066	S-Ruxolitinib	1160597-27-2	Selective	JAK1	3.2 nM	Phase 4	Myelofibrosis (PMF); Splenomegaly
T2398	Tofacitinib Citrate (CP-690550)	540737-29-9	Selective	JAK3	1 nM	FDA Approved	
T3069	AZD1480	935666-88-9	Selective	JAK2	112 nM	Phase 1	Myelopro liferative Diseases
T1995	Fedratinib (SAR302503, TG101348)	936091-26-8	Selective	JAK2 (V617F)	0.26 nM	Phase 2	

STAT

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2505	S3I-201; NSC 74859	501919-59-1	Selective	STAT3	86 μ M		
T1038	Fludarabine	21679-14-1	Selective	STAT1	N/A	FDA Approved	
T6308	Stattic	19983-44-9	Selective	STAT1	5.1 μ M		
T0711	Niclosamide	50-65-7	Selective	STAT	0.7 μ M	FDA Approved	
T2814	Cryptotanshinone	35825-57-1	Selective	STAT3	4.6 μ M		

PI3K Inhibitor

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2235	BEZ235 (Dactolisib)	915019-65-7	Pan	p110 α	4 nM	Phase2	Pancreatic Neuroendocrine Tumors
				p110 γ	5 nM		
				p110 δ	7 nM		
T1994	GDC-0941	957054-30-7	Selective	p110 α	3 nM	Phase2	Breast Cancer; Non-Squamous Non-Small Cell Lung Cancer
				p110 β	33 nM		
				p110 δ	3 nM		
T2008	LY294002	154447-36-6	Pan	p110 α	0.5 μ M		
				p110 β	0.97 μ M		
				p110 δ	0.57 μ M		
T1827	BKM120 (NVP-BKM120, Buparlisib)	944396-07-0	Pan	p110 α	52 nM	Phase2	Breast Cancer
				p110 β	166 nM		
				p110 δ	116 nM		
T1879	3-Methyladenine (3-MA)	5142-23-4	Pan	Vps34	25 μ M		
				p110 γ	60 μ M		
T2308	HS-173	1276110-06-5	Selective	p110 α	0.8 nM		
T2661	TGX-221	663619-89-4	Selective	p110 β	5 nM		
T1949	CZC24832	1159824-67-5	Selective	p110 γ	27 nM		
T1894	CAL-101 (Idelalisib, GS-1101)	870281-82-6	Selective	p110 δ	2.5 nM	FDA Approved	

Akt Inhibitor

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1952	MK-2206 2HCl	1032350-13-2	Pan	Akt1	8 nM	Phase2	
				Akt2	12 nM		
				Akt3	65 nM		
T1920	AZD-5363	1143532-39-1	Pan	Akt1	3 nM	Phase2	
				Akt2	8 nM		
				Akt3	8 nM		
T2492	Perifosine (KRX-0401)	157716-52-4	Pan	Akt	4.7 μ M	Phase3	

ATM/ATR

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T3032	VE-821	1232410-49-9	Selective	ATM	12.9 nM		
T2685	KU55933	587871-26-9	Selective	ATM	6.3 nM		
T2474	KU-60019	925701-49-1	Selective	ATR	26 nM		
T2669	VE822	1232416-25-9	Selective	ATR	19 nM		
T1958	AZ20	1233339-22-4	Selective	ATR	5 nM		

For more products information, please check our website of "www.targetmol.com".

mTOR Inhibitor


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1784	Everolimus (RAD001)	159351-69-6	Pan	mTOR	1.6-2.4 nM	FDA approved	
T1859	AZD8055	1009298-09-2	Pan	mTOR	0.8 nM	Phase1	Solid Tumors: Glioblastoma Multiforme
T1537	Rapamycin (Sirolimus)	53123-88-9	Pan	mTOR	0.1 nM	FDA approved	
T2145	Temsirolimus (CCI-779, NSC 683864)	162635-04-3	mTORC1 Selective	mTOR	1.76 μ M	FDA approved	
T1838	INK 128 (MLN0128)	1224844-38-5	Pan	mTOR	1 nM	Phase2	Thyroid Cancer; Prostate Cancer; Breast Cancer

GSK-3 inhibitor

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2310	CHIR-99021 HCL	252917-06-9	Pan	GSK-3 α	10 nM		
				GSK-3 β	6.7 nM		
T3077	SB216763	280744-09-4	Pan	GSK-3 α	34.3 nM		
				GSK-3 β	~34.3 nM		
T2166	TWS119	601514-19-6	Selective	GSK-3 β	30 nM		
T1917	6-BIO	667463-62-9	Pan	GSK-3 α	5 nM		
				GSK-3 β	5 nM		
T2608	CHIR-98014	252935-94-7	Pan	GSK-3 α	0.65 nM		
				GSK-3 β	0.58 nM		
T1957	AZD2858	486424-20-8	Pan	GSK-3	68 nM		
T1881	AR-A014418	487021-52-3	Selective	GSK-3 β	104 nM		
T3067	Tideglusib	865854-05-3	Selective	GSK-3 β	60 nM	Phase2	

For more products information , please check our website of "www.targetmol.com".

Tyrosine Kinase/Adaptors



For more products information, please check our website of "www.targetmol.com".

VEGFR

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1797	XL184 (Cabozantinib malate)	1140909-48-3	Selective	VEGFR2	0.035 nM	FDA Approved	Renal cancer; Thyroid cancer
T1656	Vandetanib (ZD6474)	443913-73-3	Selective	VEGFR2	40 nM	FDA Approved	Thyroid cancer
T1452	Axitinib	319460-85-0	Pan	VEGFR1 VEGFR2 VEGFR3	0.1 nM 0.2 nM 0.1-0.3 nM	FDA Approved	Renal cancer
T1777	Nintedanib (BIBF 1120)	656247-17-5	Pan	VEGFR1 VEGFR2 VEGFR3	34 nM 13 nM 13 nM	Phase 3	Idiopathic pulmonary fibrosis; Non-small cell lung cancer
T2421 	SKLB1002	1225451-84-2	Selective	VEGFR2	32 nM		

c-MET

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1661	Crizotinib	877399-52-5	Non-specific	c-MET ALK	11 nM 24 nM	FDA Approved	Non-small cell lung cancer
T3113	Foretinib (GSK1363089)	849217-64-7	Non-specific	Met KDR	0.4 nM 0.9 nM	Phase 2	Cancer
T2293	SGX-523	1022150-57-7	Selective	Met	4 nM	Phase 1	Solid tumours
T1963	INCB28060 (Capmatinib)	1029712-80-8	Selective	c-Met	0.13 nM	Phase 2	Glioblastoma; Hepatocellular carcinoma; Non-small cell lung cancer

Bcr-Abl

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1621	Imatinib Mesylate (STI571)	220127-57-1	Non-specific	v-Abl c-Kit PDGFR	600 nM 100 nM 100 nM	FDA Approved	Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
T1448L	Dasatinib monohydrate	863127-77-9	Non-specific	Abl Src	<1 nM 0.8 nM	FDA Approved	
T1524	Nilotinib (AMN-107)	641571-10-0	Selective	Bcr-Abl	<30 nM	FDA Approved	Chronic myeloid leukaemia
T1803 	GNF-5	778277-15-9	Selective	Bcr-Abl	220 nM		

For more products information, please check our website of "www.targetmol.com".

PDGFR

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6230	Imatinib (STI571)	152459-95-5	Pan	PDGFR c-Kit	100 nM 100 nM	FDA Approved	
T0374	Sunitinib Malate	341031-54-7	Selective	PDGFR β	2 nM	FDA Approved	Gastrointestinal stromal tumours; Pancreatic cancer; Renal cancer
T2677	Crenolanib (CP-868596)	670220-88-9	Pan	PDGFR α PDGFR β	2.1 nM 3.2 nM	Phase 3	Acute myeloid leukaemia; Gastrointestinal stromal tumours
T6184	TSU-68 (SU6668, Orantinib)	252916-29-3	Selective	PDGFR β	8 nM	Phase 3	Solid tumours
T1452	Axitinib	319460-85-0	Pan	PDGFR β c-Kit	1.6 nM 1.7 nM	FDA Approved	Renal cancer

FGFR

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1975	BGJ398 (NVP-BGJ398)	872511-34-7	Pan	FGFR1 FGFR2 FGFR3 FGFR3 (K650E)	0.9 nM 1.4 nM 1.0 nM 4.9 nM	Phase 2	Bladder cancer; Cholangiocarcinoma; Glioblastoma; Haematological malignancies
T2642	PD173074	219580-11-7	Selective	FGFR1	0.37 nM		
T1948	AZD4547	1035270-39-3	Pan	FGFR1 FGFR2 FGFR3 FGFR4	0.2 nM 1.5 nM 2.8 nM 165 nM	Phase 2/3	Non-small cell lung cancer
T6082 NEW	SSR128129E	848318-25-2	Selective	FGFR1	1.9 μ M		

HER2

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T0078L	Lapatinib ditosylate	388082-78-8	Pan	EGFR/ErbB2 HER2/ErbB2	10.8 nM 9.8 nM	FDA Approved	Breast cancer
T2325	Neratinib (HKI-272)	698387-09-6	Pan	EGFR/ErbB2 HER2/ErbB2	92 nM 59 nM	Phase 2	

For more products information, please check our website of "www.targetmol.com".

ALK


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2251	TAE684 (NVP-TAE684)	761439-42-3	Selective	ALK	3 nM		
T1936	Alectinib (CH5424802)	1256580-46-7	Mutant-targeted	ALK	1.9 nM	FDA Approved	Non-small cell lung cancer
				ALK(F1174L)	1 nM		
				ALK(3,5)	3.5 nM		
T1791	LDK378(Ceritinib)	1032900-25-6	Selective	ALK	0.2 nM	Phase 3	
				InsR	7 nM		
				IGF-1R	8 nM		
T1962 	ASP 3026	1097917-15-1	Non-specific	ALK	3.5 nM		

FLT3

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2066	Quizartinib (AC220)	950769-58-1	Mutant-targeted	FLT3(WT)	4.2 nM	Phase 3	Acute myeloid leukaemia
				FLT3(ITD)	1.1 nM		
T2341	KW2449	1000669-72-6	Mutant-targeted	FLT3	6.6 nM	Phase 1	
				FLT3(D835Y)	1 nM		
				Abi	14 nM		
				Abi(t315i)	4 nM		

For more products information, please check our website of "www.targetmol.com".

MAPK Signaling



MEK

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6218	Selumetinib (AZD6244)	606143-52-6	Selective	MEK1	14 nM	Phase 1	Solid Tumours
T6189	PD0325901	391210-10-9	Pan	MEK	0.33 nM	Phase 2	
T2125	Trametinib (GSK1120212)	871700-17-3	Pan	MEK1	0.92 nM	FDA Approved	Malignant melanoma
				MEK2	1.8 nM		
T2443	PD184352(CI-1040)	212631-79-3	Pan	MEK1	17 nM	Phase 2	
				MEK2	17 nM		
T2623	PD 98059	167869-21-8	Selective	MEK1	1 μM		
T6636	Refametinib (RDEA119, Bay 86-9766)	923032-37-5	Pan	MEK2	19 nM	FDA Approved	Neoplasms
				MEK1	47 nM		

For more products information, please check our website of "www.targetmol.com".

Raf

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1903	Dabrafenib (GSK2118436)	1195765-45-7	Mutant-targeted	B-Raf(V600E)	0.8 nM	FDA Approved	Neoplasms, Brain
				B-Raf	3.2 nM		
				C-Raf	5 nM		
T0093L	Sorafenib	284461-73-0	Pan	Raf-1	6 nM	FDA Approved	Hepatocellular Carcinoma
				B-Raf	22 nM		
				B-Raf(V599E)	38 nM		
				VEGFR2/Flk1	15 nM		
T0093	Sorafenib tosylate	475207-59-1	Pan	Raf-1	6 nM	FDA Approved	
				B-Raf	22 nM		
				B-Raf(V599E)	38 nM		
				VEGFR2/Flk1	15 nM		
T2382	Vemurafenib (PLX4032, RG7204)	918504-65-1	Mutant-targeted	B-Raf(V600E)	31 nM	FDA Approved	
				B-Raf	100 nM		
				C-Raf	48 nM		
T2473	PLX4720	918505-84-7	Mutant-targeted	C-Raf-1 (Y340D/Y341D)	6.7 nM		
				B-Raf(V600E)	13 nM		
				B-Raf	160 nM		

p38 MAPK


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2301	SB202190 (FHPI)	152121-30-7	Pan	p38 α MAPK	50 nM		
				p38 β MAPK	100 nM		
T6277	BIRB 796 (Doramapimod)	285983-48-4	Selective	p38 α MAPK	0.1 nM		
T1764	SB203580	152121-47-6	Pan	p38 MAPK	0.3-0.5 μ M		
				PKB	3-5 μ M		
T6047	LY2228820	862507-23-1	Selective	p38 α MAPK	7 nM	Phase 1/2	
T1974	PH797804	586379-66-0	Pan	p38 α MAPK	26 nM	phase 2	
				p38 β MAPK	102 nM		

ERK

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1956	FR180204	865362-74-9	Selective	ERK1	Ki(0.31 μ M)		
				ERK2	Ki(0.14 μ M)		
T6066 NEW	SCH772984	942183-80-4	Selective	ERK1	4 nM		
				ERK2	1 nM		
T6511	GDC-0994	1453848-26-4	Selective	ERK1	1.1 nM	Phase 1	
				ERK2	0.3 nM		

For more products information , please check our website of "www.targetmol.com".

Cell Cycle/Checkpoint



For more products information, please check our website of "www.targetmol.com".

CDK

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1785	Palbociclib	571190-30-2	Pan	CDK4/ CyclinD3 CDK4/ CyclinD1 CDK6/ CyclinD2	9 nM 11 nM 15 nM	FDA Approved	Breast cancer
T2095	Roscovitine (CYC202, Seliciclib)	186692-46-6	Pan	CDK5/p35 Cdc2/ CyclinB CDK2/ CyclinA CDK2/ CyclinE	0.16 μ M 0.65 μ M 0.7 μ M 0.7 μ M	Phase 2	Non-small Cell Lung Cancer
T1912	Dinaciclib (SCH727965)	779353-01-4	Pan	CDK1 CDK2 CDK5 CDK9	3 nM 1 nM 1 nM 4 nM	Phase 3	Chronic lymphocytic leukaemia
T1901 	TG003	300801-52-9	Pan	Clk1 Clk2 Clk4	20 nM 200 nM 15 nM		
T6563	LDC000067	1073485-20-7	Selective	CDC7	3.4 nM		
T6735	XL413 (BMS-863233)	1169562-71-3	Selective	CDK9	44 nM		

Chk

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6093	AZD7762	860352-01-8	Pan	Chk1 Chk2	5 nM <10 nM	Phase 1	
T6084	LY2603618	911222-45-2	Selective	Chk1	N/A	Phase 2	
T6350	CHIR-124	405168-58-3	Selective	Chk1 Chk2	0.3 nM 697.4 nM		
T6028	PF-477736	952021-60-2	Selective	Chk1 Chk2	Ki(0.49 nM) Ki(47 nM)	Phase 1	

PLK


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6173	BI 2536	755038-02-9	Pan	Plk1 Plk2 Plk3	0.83 nM 3.5 nM 9 nM	Phase 2	
T2704	MLN0905	1228960-69-7	Selective	Plk1	2 nM		
T2634	Ro3280	1062243-51-9	Selective	Plk1	3 nM		
T6019	Volasertib (BI 6727)	755038-65-4	Selective	Plk1	0.87 nM	Phase 3	Acute myeloid leukaemia
T6070	Rigosertib (ON-01910)	1225497-78-8	Selective	Plk1	9 nM	Phase 3	
T6282	GSK461364	929095-18-1	Selective	Plk1	Ki(2.2 nM)	Phase 1	

For more products information, please check our website of "www.targetmol.com".

Rock

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1725	Y-27632 2HCl	129830-38-2	Pan	ROCK1	140 nM		
				ROCK2	300 nM		
T3060	Fasudil (HA-1077) HCl	105628-07-7	Non-specific	ROCK2	0.33 μM	FDA Approved	Cerebral ischaemia; Cerebral vasospasm
				PKA	1.6 μM		
				PKG	1.6 μM		
				PKC	3.3 μM		
T2155	Thiazovivin	1226056-71-8	Pan	ROCK	~0.5 μM		
T1898	RKI-1447	1342278-01-6	Pan	ROCK1	14.5 nM		
				ROCK2	6.2 nM		
T2633	GSK429286A	864082-47-3	Pan	ROCK1	14 nM		
				ROCK2	63 nM		

Stem Cell



For more products information, please check our website of "www.targetmol.com".


TGF-beta/ Smad

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1726	SB 431542	301836-41-9	Selective	ALK5	94 nM		
T1935	LDN-193189	1062368-24-4	Pan	ALK2	20 nM		
				ALK3	30 nM		
T1763	SB525334	356559-20-1	Selective	TGF β R1/ALK5	14.3 nM		
T1900 NEW	LDN212854	1432597-26-6	Pan	ALK1	2.4 nM		
				ALK2	1.3 nM		
				ALK3	85.8 nM		
				ALK4	2133 nM		

Wnt beta-catenin

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1878	XAV939	284028-89-3	Selective	TNKS1	11 nM		
				TNKS2	4 nM		
T2242	Wnt-C59	1243243-89-1	Selective	Porcn	74 Pm		
T2618	LGK-974	1243244-14-5	Pan	Porcn	0.4 nM	Phase 2	Colorectal cancer

Apoptosis



For more products information, please check our website of "www.targetmol.com".

Bcl-2

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2101	ABT-263 (Navitoclax)	923564-51-6	Pan	Bcl-XI	(Ki) ≤ 0.5 nM	Phase 2	
				Bcl-2	(Ki) ≤ 1 nM		
				Bcl-W	(Ki) ≤ 1 nM		
T6275	Obatoclax Mesylate (GX15-070)	803712-79-0	Selective	Bcl-2	220 nM		
T2099	ABT-737	852808-04-9	Pan	Bcl-XI	78.7 nM	Phase 2	
				Bcl-2	30.3 nM		
				Bcl-W	197.8 nM		
T2119	ABT-199 (GDC-0199)	1257044-40-8	Selective	Bcl-XI	(Ki)<0.01nM	FDA Approved	Chronic lymphocytic leukaemia
				Bcl-2	(Ki)<48 nM		
				Bcl-W	(Ki)<246 nM		
				Mcl-1	(Ki)>444 nM		
T1980	HA14-1	65673-63-4	Selective	Bcl-2	$\sim 9 \mu\text{M}$		

p53


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2707	Pifithrin- α	63208-82-2	Pan	p53	N/A		
T1919	Tenovin-1	380315-80-0	Pan	p53	Activator		
T1798	RITA (NSC 652287)	213261-59-7		MDM2			
				p53			

TNF- α

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1642	Lenalidomide (CC-5013)	191732-72-6	Lenalidomide is a TNF- α secretion inhibitor with IC50 of 13 nM			FDA Approved	Cancer
T2384	Pomalidomide	19171-19-8	Pomalidomide inhibits TNF- α release that induced by LPS with IC50 of 13 nM			FDA Approved	
T1847	Necrostatin-1	4311-88-0	Necrostatin-1 is a specific RIP1 inhibitor and inhibits the necroptosis that induced by TNF- α with EC50 of 490 nM				

For more products information , please check our website of "www.targetmol.com".


Ubiquitination



ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1924	LDN-57444	668467-91-2	Pan	UCH-L1	0.88 μM		
				UCH-L3	25 μM		
T1932	B-AP15	1009817-63-3	Pan	USP14	N/A		
				UCH-L5	2.1 μM		
T1757	ML323	1572414-83-5	Selective	USP1-UAF1	76 nM		

For more products information, please check our website of "www.targetmol.com".

Angiogenesis



BTK

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1835	Ibrutinib (PCI-32765)	936563-96-1	Non-specific	BTK	0.5 nM	FDA Approved	Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
				BLK	0.5 nM		
				Bmx	0.8 nM		
				CSK	2.3 nM		
T2302 NEW	CNX-774	1202759-32-7	BTK	<1 nM			
T2472 NEW	CGI1746	910232-84-7	BTK	1.9 nM			
T2603 NEW	CC-292 (AVL-292)	1202757-89-8	BTK	<0.5nM		Phase 1	Rheumatoid arthritis

Syk


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2467	R406	841290-80-0	Selective	Syk	41 nM	Phase 3	Immune thrombocytopenic purpura
T2605	R788(Fostamatinib) Disodium	1025687-58-4	Selective	Syk	42 nM	Phase 3	Immune thrombocytopenic purpura
T2696	PRT062607 (P505-15, BIIB057) HCl	1370261-97-4	Selective	Syk	1 nM	Phase 1	
				FGR	81 nM		
				MLK1	88 nM		
				YES	123 nM		

For more products information, please check our website of "www.targetmol.com".

Src

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1448	Dasatinib	302962-49-8	Non-specific	Src	0.8 nM	FDA Approved	Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
				Abl	0.6 nM		
				c-Kit	79 nM		
T6078	Saracatinib (AZD0530)	379231-04-6	Non-specific	c-Src	2.7 nM	Phase 2	Alzheimer's disease; Breast cancer; Cancer pain; lymphangioleiomyomatosis
				Lck	<4 nM		
				c-Yes	<4 nM		
				Lyn	5 nM		
T0152	Bosutinib	380843-75-4	Non-specific	Src	1.2 nM	FDA Approved	Chronic myeloid leukaemia
				Abl	1 nM		

Immunology/Inflammation




NF- κ b

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1930	JSH-23	749886-87-1	Selective	NF- κ b	7.1 μ M		
T0020	Sodium 4-A minosalicylate	6018-19-5		Sodium 4-Aminosalicylate is an antibiotic used to treat tuberculosis via NF- κ B inhibition and free radical scavenging.			

For more products information , please check our website of "www.targetmol.com".

Membrane Transporter/Ion Channel




CFTR

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1805	Ataluren (PTC124)	775304-57-9	PTC124 (Ataluren) selectively induces ribosomal read-through of premature but not normal termination codons, with EC50 of 0.1 μ M, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation).			FDA Approved	Duchenne muscular dystrophy
T2355	CFTRinh-172	307510-92-5	Selective	CFTR	(Ki)300 nm		

For more products information, please check our website of "www.targetmol.com".

DNA Damage/DNA Repair




DNA/ RNA Synthesis

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1564	Cisplatin	15663-27-1		Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts		Phase 1	Solid tumours
T0251	Gemcitabine	95058-81-4	Pan	PANC1	50 nM	FDA Approved	Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
				MIAPaCa2	40 nM		
				BxPC3	18 nM		
				Capan2	12 nM		
T6116	Bleomycin Sulfate	9041-93-4		Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for SCC with IC50 of 4 nM		Phase 3	Hodgkin's disease
T0164	Oxaliplatin	61825-94-3		Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts		FDA Approved	Colorectal cancer

For more products information, please check our website of "www.targetmol.com".

Neuroscience




Gamma-Secretase

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6202	DAPT (GSI-IX)	208255-80-5	Selective	γ -secretase [α β]	20 nM		
T2625	MK0752	471905-41-6	Selective	α β 40	5 nM	Phase 1	Breast cancer; CNS cancer; Pancreatic cancer; Solid tumours
T3075 NEW	FLI-06	313967-18-9	Selective	Notch	2.9 μ M		

For more products information , please check our website of "www.targetmol.com".

Microbiology & Virology




ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T0100L	Atazanavir	198904-31-3	Antiretroviral	Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.		FDA Approved	HIV infection
T1525	Ritonavir	155213-67-5	Antiretroviral	Ritonavir is an antiretroviral (HIV) drug which inhibits a particular liver enzyme that normally metabolizes protease inhibitors, cytochrome P450-3A4 (CYP3A4).		FDA Approved	
T1623	Lopinavir	192725-17-0	Antiretroviral	Lopinavir (also known as ABT-378) is a highly potent inhibitor of human immunodeficiency virus (HIV) protease that potently inhibits wild-type and mutant HIV protease		FDA Approved	
T2162	Maribavir	176161-24-3	Antiviral	Maribavir (GW257406X; BW1263W94; 1263W94) inhibits HCMV replication by inhibition of an HCMV encoded protein kinase enzyme called UL97 or pUL97.		Phase 2	CMV infections
T1786	Daclatasvir, BMS 790052	1009119-65-6	Antiviral	BMS-790052 is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.		FDA Approved	HCV infection

For more products information, please check our website of "www.targetmol.com".

DNA/ RNA Synthesis

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T1564	Cisplatin	15663-27-1	Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts			Phase 1	Solid tumours
T0251	Gemcitabine	95058-81-4	Pan	PANC1	50 nM	FDA Approved	Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
				MIAPaCa2	40 nM		
				BxPC3	18 nM		
				Capan2	12 nM		
T6116	Bleomycin Sulfate	9041-93-4	Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for SCC with IC50 of 4 nM			Phase 3	Hodgkin's disease
T0164	Oxaliplatin	61825-94-3	Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts			FDA Approved	Colorectal cancer

GPCR/G Protein



For more products information , please check our website of "www.targetmol.com".

Hedgehog Smoothened


ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T2299	BMS-833923	1059734-66-5	Selective	Smoothened (antagonist)		Phase 2	
T2666	Taladegib (LY2940680)	1258861-20-9	Selective	Smoothened		Phase 1/2	
T2590	Vismodegib (GDC-0449)	879085-55-9	Selective	Hedgehog	3 nM		
T1926	LDE225 (NVP-LDE225, Erismodegib)	956697-53-3	Selective	Smoothened (Mouse)	1.3 nM	Phase 3	
				Smoothened (Human)	2.5 nM		

Adrenergic

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T0101	Doxazosin mesylate	77883-43-3	Selective	α 1-adrenergic		FDA Approved	Cocaine Dependence; Prostatic Hyperplasia
T1056	Isoprenaline HCl	51-30-9	Pan	β -adrenergic agonist		FDA Approved	
T0487	Metoprolol tartrate	56392-17-7	Selective	β -adrenergic	42 ng/ml	FDA Approved	Hypertension

For more products information , please check our website of "www.targetmol.com".

Endocrinology/ Hormones



Androgen Receptor

ID	Product Name	Cas Number	Type	Target	IC50	Clinical Trail	Condition
T6002	Enzalutamide (MDV3100)	915087-33-1	Selective	Abdrigeb Receptor	36 nM	FDA Approved	Prostate cancer
T0380	Bicalutamide	90357-06-5	Selective	Abdrigeb Receptor	0.16 μ M	FDA Approved	Prostate cancer
T2339	ARN-509	956104-40-8	Selective	Abdrigeb Receptor GAPAA Receptor	16 nM 3000 nM	Phase 3	Prostate cancer
T1167	Cyproterone acetate	427-51-0	Selective	Abdrigeb Receptor	7.1 nM		

For more products information , please check our website of "www.targetmol.com".

Enzyme

Carbonic anhydrase	Hydrogenase	PP2A
Cathepsin K	Hydrolase	Reductase
LXR	Hydroxylase	Squalene epoxidase
CzcO-like	sGC	Tyrosinase
DHPS	Oxidosqualene cyclase	VKOR
Endopeptidase	Peroxiredoxin-5	
Hexokinase	Phosphorylase	

Others

ACCase	MCT	RAGE
Adrenodoxin	MELK	Ryanodine receptor
AGE	mTOT	SAA
APN	Oct3/4	SGK1;SGK2
ATX	PCSK9	SRPK1
BMI-1	Pepsin	TTR
Calcineurin phosphatase	PFKFB3	Xylose isomerase
CART	p-HBH	α -glucosidase
DYRK	Phytoestrogen	Others
Lysozyme	PPM1D	
MALT1	Purine nucleoside phosphorylase	


For more products information, please check our website of "www.targetmol.com".

Cat. No. L1000 Approved Drug Library



- A unique collection of 1600 approved drugs
- Identify new targets for previously discovered drugs;
- Bioactivity and safety confirmed by clinical trials;
- All compounds have been approved;
- Compounds have applications in a wide range of fields, including oncology, cardiology, immunology, endocrinology, etc.;
- Accelerate drug optimization and discovery;
- Extensive compound documentation, including structure and IC50 value, as well as customer reviews;
- Save time and budget.

Research fields:



- | | |
|-------------------|----------------------|
| ■ Immunology | ■ Others |
| ■ Neuropsychiatry | ■ Oncology |
| ■ Metabolism | ■ Endocrinology |
| ■ Cardiology | ■ Respiratory system |

Database Contains:

- CAS, Chemical name, 3D structure, Formula, Solubility;
- Bioactivity, Targets, IC50 Value, References, Clinical Data;
- COA, MSDS, Datasheet, NMR, LCMS, HPLC, etc.

Headquarters

North America



United States

Order & Inquiry

Tel: 857-239-0968

Fax: 857-239-8801

Email: info@targetmol.com

Add: One Boston Place Suite 2600 Boston, MA 02108

Technical Support

E-mail: tech@targetmol.com

Europe



Germany

Order & Inquiry

Tel: +0049-0163-1922118

E-mail: eu.order@targetmol.com

Add: Willi-Graf-Str. 25/384 80805/Munich

Asia Pacific region



China

Order & Inquiry

E-mail: sales@targetmol.com

Tel: 400-998-7375

Fax: 021-34692979

Add: NO 228 Jiangchang San Road ,Shanghai,China



Target Molecule Corp.

---Drug Screening Expert(Inhibitors, Libraries, Natural Compounds)

www.targetmol.com